The expression of PD-L1 on tumor cells in RCC is associated with a higher tumor stage, a worse response to tyrosine kinase inhibitor (TKI) therapy, and a worse prognosis [17,18,19,20,21,22,23]. The gene discussed is CD274; the disease is renal cell carcinoma.